Search
Baclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigational[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
Categories: GABA-B Receptor AgonistsZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Pegulicianine
go.drugbank.com/drugs/DB18731ApprovedInvestigational[L50537] Pegulicianine (under the brand name Lumisight) was approved for use by the FDA in April 2024.[L50537,L50547] It received Fast Track and priority review for this indication.[L50547]
Zolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigational[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. … Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.
Categories: Serotonin Receptor Agonists, Serotonin 1b Receptor AgonistsProducts: Nra-zolmitriptanProchlorperazine
go.drugbank.com/drugs/DB00433ApprovedInvestigationalVet approved[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956.
Categories: Dopamine D2 Receptor AntagonistsTedizolid phosphate
go.drugbank.com/drugs/DB09042Approved[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Dosulepin
go.drugbank.com/drugs/DB09167ApprovedInvestigationalIt is not FDA-approved due to low therpeutic index and significant toxicity in overdose.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor AntagonistsBenzethonium
go.drugbank.com/drugs/DB11125ApprovedFood and Drug Administration (FDA). It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments.
Ibrexafungerp
go.drugbank.com/drugs/DB12471Approved[A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist.
Categories: Adrenergic beta-2 Receptor Agonists, Adrenergic beta-3 Receptor Agonists